Biorce Secures €44M Series A to Transform Clinical Trials with AI

Team S · 2026-02-06T13:04:03.000Z

Biorce, a Barcelona-based health technology startup that applies artificial intelligence to clinical trial design and execution, has announced the successful closing of a €44 million (approximately $52.5 million) Series A funding round the largest Series A in the Iberian healthtech and AI ecosystem to date. The capital will support Biorce’s international expansion, enhance its AI platform, and accelerate growth of its engineering and commercial teams in key markets including the United States. The financing round was led by DST Global Partners, with participation from returning investors such as Norrsken VC, YZR Capital, and Mustard Seed Maze (MSM), alongside contributions from Endeavor Catalyst and several high-profile angel investors. Among the notable angels backing the company are Nik Storonsky (CEO of Revolut), Arthur Mensch (co-founder and CEO of Mistral AI), Paulo Rosado (founder of OutSystems), and Albert Nieto (founder of Seedtag) all highlighting deep cross-sector confidence in Biorce’s mission to modernize clinical research. Founded in 2024, Biorce has developed Aika, an AI-native platform designed to streamline protocol development, site selection, and feasibility assessment for clinical trials, significantly reducing timelines and costs. With this Series A funding, the company plans to scale its team to around 250 employees by the end of 2026, open an R&D hub in Austin, Texas, and drive broader adoption of its AI solutions across diverse therapeutic areas including oncology and rare diseases.

Member Login Get Access

Biorce Secures €44M Series A to Transform Clinical Trials with AI | Newnex